# A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

> **NCT06682988** · PHASE2 · RECRUITING · sponsor: **AbbVie** · enrollment: 110 (estimated)

## Conditions studied

- Advanced High-Grade Epithelial Ovarian
- Primary Peritoneal
- Fallopian Tube Cancers
- High Folate Receptor-Alpha Expression
- Platinum Resistant

## Interventions

- **DRUG:** Mirvetuximab Soravtansine

## Key facts

- **NCT ID:** NCT06682988
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-28
- **Primary completion:** 2028-03
- **Final completion:** 2028-03
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06682988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06682988, "A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06682988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*